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Cytokinesa b s t r a c t
A rare, multisystem, plasma cell neoplasm, POEMS (polyradiculoneuropathy, organomegaly, endocrinopathy,
M-spike, skin changes) syndrome is characterized by an abundance of proinﬂammatory and angiogenic
cytokines. Patients with POEMS are known to have a high incidence of engraftment syndrome after autol-
ogous stem cell transplantation. We conducted a pilot study assessing levels of 30 different pro- and anti-
inﬂammatory cytokines before and serially after transplantation in 18 patients with plasma cell
neoplasms: POEMS syndrome (n ¼ 9), multiple myeloma (n ¼ 4), and amyloidosis (n ¼ 5). We show that
POEMS patients have higher pretransplantation levels of IL-4, IL-10, IL-13, IFN-a, and EGF as compared with
those with non-POEMS plasma cell neoplasms. Higher pre- and posttransplantation IL-13 levels correlated
with delayed neutrophil engraftment in POEMS patients. Low posttransplantation IL-1RA levels correlated
with engraftment syndrome in both POEMS and non-POEMS patients. We conclude that differences in the
peri-transplantation cytokine milieu may explain the higher transplantation morbidity in patients with
POEMS syndrome. Our results need validation in a larger cohort.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
POEMS syndrome (polyradiculoneuropathy, organo-
megaly, endocrinopathy, M-spike, skin changes) is a poorly
understood multisystem paraneoplastic disorder secondary
to a plasma cell neoplasm [1]. The hallmark of this complex
disease is the presence of angiogenic and proinﬂammatory
cytokines, such as vascular endothelial growth factor (VEGF),
IL-1b, IL-6, and TNF-a seen in patients with POEMS when
Table 1
Baseline and Transplantation Characteristics of the Two Groups
Characteristic POEMS
(n ¼ 9)
Non-POEMS
(n ¼ 9)
P
Value
Age, median (range), yr 52 (35 to 68) 62 (50 to 70) NS
Gender, male, % 44 89 .05
KPS (range) POEMS 70
(50-80)
Non-POEMS
90 (70-100)
.001
Splenomegaly 5 (56) 0 .009
Extravascular ﬂuid
overload
9 (100) 4 (44) .009
Lambda restricted 9 (100) 4 (44) .009
Prior treatments,
median (range)
2 (1 to 4) 1 (0 to 7) NS
Mobilization NS
Cy/G-CSF 1 (11) 2 (22)
G-CSF 8 (89) 6 (67)
G-CSF/plerixafor 0 1 (11)
Conditioning NS
Mel 140 3 (33) 2 (22)
A. Keyzner / Biol Blood Marrow Transplant 19 (2013) 1393e14111396compared with normal controls and with other plasma cell
proliferative disorders [2-5]. High-dose chemotherapy and
autologous stem cell transplantation (ASCT) is often the
treatment of choice in ﬁt patients with disseminated POEMS
to eliminate the plasma cell clone. However, these patients
are known to have high rates of engraftment syndrome (ES)
after ASCT [6]. ES after stem cell transplantation is associated
with increased levels of endogenous cytokines [7-9]. We
therefore postulated that patients with POEMS syndrome,
who already have an aberrant cytokine milieu, are more
prone to ES as a result of an ampliﬁed and exaggerated
cytokine response during marrow reconstitution [6]. To test
this hypothesis, we conducted the following prospective
pilot study in an attempt to better understand the underlying
cytokine ﬂuctuations in patients with POEMS syndrome
before and after ASCT in relation to patients with other
plasma cell proliferative disorders.Mel 200 6 (67) 7 (78)
CD34 dose,  106/kg,
median (range)
3.88 (2.9 to 14.6) 4.93 (3.45 to 7.49) NS
Engraftment syndrome 2 (22) 3 (33) NS
Time to engraftment,
median (range), d
ANC 15 (13 to 19) 13 (12 to 15) .006
Platelet >20 K 11.5 (9 to 20) 13 (11 to 20) NS
Platelet >50 K 14 (12 to 27) 15 (12 to 25) NS
KPS indicates Karnofsky performance status; CY, cyclophosphamide; G-CSF,
granulocyte colony-stimulating factor; mel, melphalan; ANC, absolute
neutrophil count; NS, not signiﬁcant.
Data presented as n (%) unless otherwise indicated.MATERIAL AND METHODS
This study was approved by the Mayo Foundation Institutional Review
Board, and after informed consent, research blood samples from patients
were collected and analyzed in the peri-autologous stem cell trans-
plantation setting. A total of 18 patients were studied between May 2008
and March 2009: POEMS (n ¼ 9), non-POEMS (multiple myeloma [n ¼ 4],
immunoglobulin-derived amyloidosis [n ¼ 5]). According to the study
design, heparinized plasma was collected on days -2, 1, 4, 7, 10, 17, and 20 of
ASCT and stored at 20C until use. Cytokine levels were performed
simultaneously using the BioSource Multiplex Bead Immunoassays Platform
(Human cytokine 30-PLEX) by Invitrogen. Thirty different human cytokines,
chemokines, and growth factors were measured: interleukin-1beta (IL-1b),
interleukin-1 receptor antagonist (IL-1RA), IL-2, interleukin-2 receptor (IL-
2R), IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL12 (p40/p70), IL-13, IL-15, IL-17, VEGF,
tumor necrosis factor-alpha (TNF-a), interferon-alpha (IFN-a), interferon-
receptor (IFN-R), granulocyte macrophage-colony stimulating factor (GM-
CSF), macrophage inﬂammatory protein-1alpha and beta (MIP-1a, MIP-1b),
interferon gamma inducible protein-10 (IP-10, also known as CXCL10),
monokine induced by interferon gamma (MIG, aka CXCL9), eotaxin, regu-
lated on activation, normal T cell expressed and secreted (RANTES, aka
CCL5), monocyte chemotactic protein-1 (MCP-1), endothelial growth factor
(EGF), granulocyte-colony stimulating factor, ﬁbroblast growth factor, and
hepatocyte growth factor. Results were obtained in pg/mL.
Patients’ clinical data pretransplantation, transplantation data including
mobilization and conditioning regimens, as well as posttransplantation
events were collected. The Mayo Clinic criteria [10] were used to diagnose
POEMS syndrome. ES was deﬁned using the modiﬁed Spitzer deﬁnition as
published earlier [6]. Neutrophil engraftment was deﬁned as the ﬁrst day of
an absolute neutrophil count greater or equal to 500/uL on 2 consecutive
days. Platelet engraftment was deﬁned as transfusion independent
achievement of counts greater or equal 20,000 or 50,000/uL.
Data analyses were conducted using JMP version 8.0 statistical software
(SAS Institute Inc, North Carolina). The Mann-Whitney rank-sum test was
used to detect differences between clinical characteristics of the patients
and cytokine levels. For all statistical analyses, a P value<.05 was considered
statistically signiﬁcant.
RESULTS
The pertinent baseline and transplantation characteristics
of the 18 patients in this pilot study are described in Table 1.
Patients with POEMS syndrome had a lower Karnofsky
performance score. Patients with POEMS syndrome had
baseline plasma VEGF levels measured as part of clinical
testing, with a median level of 468 pg/mL (range, 146 to
1036 pg/mL; normal, 31 to 86 pg/mL). These patients were
noted to have higher pretransplantation levels of IL-4 (14.9
versus 2.9; P ¼ .03), IL-10 (14.3 versus 10.7; P ¼ .005), IL-13
(25.1 versus undetectable; P ¼ .01), IFN-a (39.4 versus
undetectable; P¼ .01) and EGF (31.7 versus undetectable; P¼
.001), whereas lower levels of IP-10 (23.8 versus 43.1; P¼ .02)
when compared with the non-POEMS patients. The pre-
transplantation plasma VEGF levels were unremarkable
between the 2 groups (38.3 versus 30.2 pg/mL).By day þ4 after transplantation, the IL-4 equalized
between the 2 groups (POEMS versus non-POEMS), but EGF,
IFN-a, IL-13, and IL-10 continued to remain signiﬁcantly
higher in the POEMS group. Further, by day þ10, IL-10 levels
had equalized. By day þ17, only IL-13 and EGF continued to
remain signiﬁcantly higher among POEMS patients.
Patients with POEMS syndrome had delayed neutrophil
engraftment with amedian time to engraftment at 15 days as
opposed to 13 days in the non-POEMS group (P ¼ .006).
Neutrophil engraftment appeared to be delayed beyond
day þ16 in both groups correlating with signiﬁcantly higher
pre- and posttransplantation IL-13 levels (Figure 1). There
was no difference between the other cytokines that were
different at baseline that also correlated with delayed
engraftment.
ES was seen in 5 patients (POEMS [n ¼ 2], multiple
myeloma [n ¼ 1], and amyloidosis [n ¼ 2] patients). The
median time to ES was 10 days (range, 8 to 13 days).
Although baseline levels of IL-1RA were not different
between patients who developed ES versus those who did
not, lower levels of IL-1RA after transplantation on days þ1
(76 versus 214 pg/mL; P ¼ .02), þ4 (37 versus 148 pg/mL; P ¼
.02),þ7 (50 versus 145 pg/mL; P¼ .002), andþ10 (106 versus
249 pg/mL; P ¼ .04) correlated with a higher incidence of ES.
Both the POEMS patients received steroids for ES; 1 between
days þ12 to þ14, and the other between days þ12 and þ17.
None of the non-POEMS patients received steroids. The
day þ17 and þ20 IL-1RA levels were not different between
the ES and non-ES groups.DISCUSSION
Working under a hypothesis that an aberrant cytokine
milieu drives engraftment syndrome in POEMS, we set out to
analyze cytokines in the peri-transplantation setting in these
Figure 1. Higher pretransplantation and posttransplantation IL-13 levels correlated with delayed neutrophil engraftment. The y-axis represents IL-13 levels, and the
x-axis represents days, with day 0 being transplantation day. The black horizontal line represents the normal human levels of IL-13. All patients without delayed
neutrophil engraftment (top) had undetectable IL-13 levels, whereas the majority of patients with delayed neutrophil engraftment (bottom) had signiﬁcantly elevated
IL-13 levels.
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plasma cell neoplasms also undergoing ASCT. We found
multiple cytokines to be different between the POEMS and
non-POEMS groups pretransplantation. Of these cytokines
that had differences, IL-4 and IP-10 are proinﬂammatory,
whereas IL-10 and IL-13 are anti-inﬂammatory cytokines;
EGF is an angiogenic factor. The levels of VEGF were not any
different; but, presumably, this is a result of prior therapy
including corticosteroid therapy, [5] as the POEMS patients
had elevated plasma VEGF levels at the time of diagnosis.
Similarly, the levels of IL12 were not any different between
the POEMS and non-POEMS groups. IL-12 has been reported
as a biomarker of disease activity for POEMS [11]. We did not
measure baseline IL-12 levels (ie, before therapy and mobi-
lization) in our POEMS patients in this study. After trans-
plantation, levels of these elevated cytokines appeared to
equalize between the 2 groups; IL-4, IP-10 levels by day þ4,
IL-10 by day þ10, and IFN-a by day þ17.
Patients with POEMS syndrome were noted to have
a longer time to neutrophil engraftment (Table 1) [12]. This is
in accordance to our previous data [6]. IL-13 is an anti-
inﬂammatory cytokine produced by activated Th2 cells. In
allogeneic stem cell transplantation, elevated IL-13 levels
after transplantation appear to correlate for graft-versus-
host disease [13]. Although the role of IL-13 in hematopoi-
etic cell engraftment in the autologous or allogeneic setting
has not been studied before, our data suggest that elevated
IL-13 levels seen in POEMS patients may cause delayed
engraftment.Patients with ES, in both POEMS and non-POEMS groups,
had signiﬁcantly lower posttransplantation levels of IL-1RA
until day þ10, by which time all ES was seen. After that,
the levels were not different between the patients with or
without ES. IL-1RA is awell-known anti-inﬂammatory acute-
phase protein that competitively inhibits actions of IL-1,
a key regulatory cytokine of local and systemic inﬂamma-
tory responses [14]. Deﬁciency of IL-1RA can result from IL-
1RN gene mutations and causes an autoinﬂammatory
disorder, the symptoms of which are mitigated by Anakinra,
a recombinant IL-1RA [15]. Additionally, an imbalance
between IL-1b and IL-1RA has been implicated in the path-
ogenesis of a number of inﬂammatory conditions, such as
atherosclerosis, chronic active hepatitis C, inﬂammatory
bowel disease, and multiple sclerosis [16-19]. Because of the
low number of patients with ES in our cohort, we were
unable to detect a difference in ratio of IL-1b to IL-1RA in
patients who developed ES and those who didn’t. Variable
number of tandem repeat sequences (2 to 6) within the
second intron of the IL-1RA gene results in several alleles
that differ among ethnic groups or geographic populations.
The most frequent IL1RN*1 allele has 4 repeats. The IL1RN*2
allele containing 2 repeats has been found at increased
frequency in patients with inﬂammatory bowel disease
[20,21], multiple sclerosis [22], and systemic lupus eryth-
ematosus [23]. If a correlation between IL-1RA levels and the
development of ES holds true, it would be interesting to look
at allele polymorphism differences between patients with
engraftment syndrome and without.
A. Keyzner / Biol Blood Marrow Transplant 19 (2013) 1393e14111398The levels of IL-4, IL-10, IFN-a, EGF, and IP-10, which were
signiﬁcantly different pretransplantation between the
POEMS and non-POEMS groups, did not correlate with either
delayed neutrophil engraftment or ES after transplantation.
Some of these cytokines (IL-4, IL-10, IFN-a) equalized during
marrow reconstitution between the 2 groups, further
implicating the abnormal cytokine environment in POEMS.
In the current study, we did not measure cytokines before
mobilization, and, therefore, our results do not represent
a true baseline and may have been confounded by the
mobilization process. Rather, we show differences in the
cytokine environment during the peri-transplantion period
among different plasma cell dyscrasias.CONCLUSIONS
We show signiﬁcant differences in the peri-
transplantation cytokine milieu among patients with POEMS
compared with patients with other plasma cell neoplasms.
Patients who develop ES have lower levels of IL-1RA, whereas
higher levels of IL-13 may result in delayed neutrophil
engraftment. These ﬁndings have the potential to improve our
ability to predict peri-transplantation morbidity in certain
subsets of patients, but need validation in larger cohorts.ACKNOWLEDGMENTS
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